This section provides a detailed introduction of adaptive servo-ventilation (ASV), a non-invasive positive pressure ventilation method for addressing sleep-related breathing disorders (SRBD), including central sleep apnea (CSA). The paper outlines two significant clinical trials, SERVE-HF and ADVENT-HF, which yielded divergent findings about the efficacy of ASV. ASV has demonstrated efficacy in treating CSA, particularly in cases of Cheyne-Stokes breathing (CSB) and other variants of CSA. The short-term advantages of ASV encompass enhanced left ventricular ejection fraction and diminished brain natriuretic peptide (BNP) levels. The SERVE-HF research indicated a heightened mortality risk in heart failure patients with reduced ejection fraction (HFrEF); however, the later ADVENT-HF trial arrived at a contrasting conclusion. A comparison of SERVE-HF with ADVENT-HF highlights significant methodological discrepancies. Principal distinctions encompass patient selection criteria, research duration, and the ASV technology employed. These contextual factors must be considered when interpreting the data and evaluating the consequences of ASV treatment and treatment techniques.